RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2 - Concepedia

Concepedia

Publication | Closed Access

RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2

299

Citations

33

References

1998

Year

A. Osama Gaber, M. Roy First, Raymond J. Tesi, Robert S. Gaston, Robert Mendez, Laura L. Mulloy, Jimmy A. Light, Lillian W. Gaber, Elizabeth Squires, Rodney J. Taylor,

Transplantation

Abstract

Thymoglobulin was found to be superior to Atgam in reversing acute rejection and preventing recurrent rejection after therapy in renal transplant recipients.

References

	Year	Citations

Page 1